GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

Analysts were rushing to reiterate their conviction in the stock following Thursday’s blow to Zepbound and Lilly shares.

Despite beating on its earnings Thursday, pharma giant Eli Lilly (LLY) suffered a nearly 12% loss in its stock, losing more ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound ...

Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).

It's important, I think, that we don't raise the price of medicines ... loss pill to market in 2026. Eli Lilly shares rallied on the news, up 14% to $839.96. The stock is up around 8% year to ...

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE ... for the next line of drugs front ran the stock price. For example, in 2016 Lilly was trading 13 times the trailing 12 months ...

Eli Lilly stocks displayed a major rise after the announcement of a new oral weight-loss drug that has put pressure on its rival pharmaceutical companies Eli Lilly’s stock surged 16% after the ...